RASA2 ablation in T cells boosts antigen sensitivity and long-term function

Carnevale, Julia; Shifrut, Eric; Kale, Nupura; Nyberg, William A.; Blaeschke, Franziska; Chen, Yan Yi; Li, Zhongmei; Bapat, Sagar P.; Diolaiti, Morgan E.; O'Leary, Patrick; Vedova, Shane; Belk, Julia; Daniel, Bence; Roth, Theodore L.; Bachl, Stefanie; Anido, Alejandro Allo; Prinzing, Brooke; Ibanez-Vega, Jorge; Lange, Shannon; Haydar, Dalia; Luetke-Eversloh, Marie; Born-Bony, Maelys; Hegde, Bindu; Kogan, Scott; Feuchtinger, Tobias; Okada, Hideho; Satpathy, Ansuman T.; Shannon, Kevin; Gottschalk, Stephen; Eyquem, Justin; Krenciute, Giedre; Ashworth, Alan und Marson, Alexander (2022): RASA2 ablation in T cells boosts antigen sensitivity and long-term function. In: Nature, Bd. 609, Nr. 7925: S. 174-182

Abstract

The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints(1,2). Targeted gene editing has the potential to overcome these limitations and enhance T cell therapeutic function(3-10). Here we performed multiple genome-wide CRISPR knock-out screens under different immunosuppressive conditions to identify genes that can be targeted to prevent T cell dysfunction. These screens converged on RASA2, a RAS GTPase-activating protein (RasGAP) that we identify as a signalling checkpoint in human T cells, which is downregulated upon acute T cell receptor stimulation and can increase gradually with chronic antigen exposure. RASA2 ablation enhanced MAPK signalling and chimeric antigen receptor (CAR) T cell cytolytic activity in response to target antigen. Repeated tumour antigen stimulations in vitro revealed that RASA2-deficient T cells show increased activation, cytokine production and metabolic activity compared with control cells, and show a marked advantage in persistent cancer cell killing. RASA2-knockout CAR T cells had a competitive fitness advantage over control cells in the bone marrow in a mouse model of leukaemia. Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours. Together, our findings highlight RASA2 as a promising target to enhance both persistence and effector function in T cell therapies for cancer treatment.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0028-0836
• Sprache: Englisch